These data suggest that only the main regions involved in PD, namely VMB and STR, have the potential to respond to treatment with CCL3, corroborating previous findings.[40, 94, 101, 102, 103] (Figure S2A, Supporting Information). Here, CCL3 is linked to Parkinson disease.